Albuterol nebulizer for infants
Pro Research Analysisby 
Searched over 200M research papers
Albuterol Nebulizer for Infants: Efficacy and Safety
Introduction to Albuterol Nebulizer for Infants
Albuterol, a bronchodilator, is commonly used to treat wheezing and respiratory distress in infants, particularly those with bronchiolitis. This article synthesizes research findings on the efficacy and safety of nebulized albuterol in infants.
Efficacy of Nebulized Albuterol in Bronchiolitis
Clinical Recovery and Oxygen Saturation
Several studies have investigated whether nebulized albuterol enhances clinical recovery in infants with bronchiolitis. A study involving 52 infants with moderate bronchiolitis found no significant difference in oxygen saturation (Sao2) or time to meet discharge criteria between those treated with albuterol and those given a placebo . Similarly, another trial with 149 infants showed no significant differences in length of hospital stay or secondary outcomes between groups treated with albuterol, epinephrine, or saline placebo .
Respiratory Parameters and Clinical Scores
Contrastingly, some studies have reported improvements in specific respiratory parameters. For instance, a trial with 40 infants demonstrated significant improvements in accessory muscle score, respiratory rate, and oxygen saturation after albuterol administration compared to placebo . Another study with 25 infants in an emergency department setting found significant improvements in wheeze scores and total clinical scores after albuterol treatment .
Comparison with Other Administration Methods
Research comparing metered-dose inhaler (MDI) and nebulized albuterol in intubated infants found both methods equally effective in improving respiratory compliance and resistance, with no significant differences in efficacy . Additionally, a study on ventilated preterm neonates indicated that both MDI-spacer and jet nebulizer were effective, with MDI-spacer being more cost-effective and quicker to administer .
Safety of Nebulized Albuterol
Adverse Effects and Cardiotoxicity
The safety profile of nebulized albuterol has been a focus of several studies. One study involving continuous nebulized albuterol (CNA) in infants and children found no significant evidence of cardiotoxicity, although some patients had transient elevations in creatinine phosphokinase (CK) levels without clinical significance . Another study noted a slight increase in heart rate in the albuterol group compared to placebo, but no other significant side effects were reported .
Comparison with Oral Albuterol
A study comparing oral and nebulized albuterol in Egyptian infants with first-time wheezing found no significant differences in clinical outcomes, except for an increase in heart rate in the nebulized albuterol group . This suggests that while nebulized albuterol is effective, it does not offer a clear advantage over oral administration in terms of efficacy.
Conclusion
The use of nebulized albuterol in infants with bronchiolitis shows mixed results regarding its efficacy. While some studies report improvements in specific respiratory parameters, others find no significant benefits in clinical recovery or length of hospital stay. The safety profile of nebulized albuterol appears favorable, with minimal adverse effects reported. However, the decision to use nebulized albuterol should be based on individual clinical scenarios and consideration of alternative treatments.
Sources and full results
Most relevant research papers on this topic